|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1280388972 |
| 003 |
OCoLC |
| 005 |
20231120010611.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
211026s2021 ne ob 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|e pn
|c YDX
|d YDX
|d OPELS
|d EBLCP
|d OCLCF
|d OCLCO
|d OCLCQ
|d UKMGB
|d UKAHL
|d CASUM
|
| 015 |
|
|
|a GBC1E6383
|2 bnb
|
| 016 |
7 |
|
|a 020313411
|2 Uk
|
| 019 |
|
|
|a 1280459782
|a 1280598375
|a 1285686362
|a 1289816766
|
| 020 |
|
|
|a 9780323989282
|q (electronic bk.)
|
| 020 |
|
|
|a 0323989284
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323989275
|
| 035 |
|
|
|a (OCoLC)1280388972
|z (OCoLC)1280459782
|z (OCoLC)1280598375
|z (OCoLC)1285686362
|z (OCoLC)1289816766
|
| 050 |
|
4 |
|a RC386
|b .B73 2021
|
| 082 |
0 |
4 |
|a 616.81
|2 23
|
| 245 |
0 |
0 |
|a Brain protection strategies and nanomedicine /
|c edited by Hari Shanker Sharma, Aruna Sharma.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Amsterdam, Netherlands ;
|a Cambridge, MA, United States :
|b Elsevier,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Progress in brain research ;
|v volume 266
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
0 |
|
|a Online resource; title from digital title page (viewed on November 01, 2021).
|
| 505 |
0 |
|
|a Intro -- Progress in Brain Research -- Copyright -- Contributors -- Contents -- Acknowledgments -- Preface -- References -- Chapter 1: Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of ... -- 1. Introduction -- 1.1. Histaminergic system in the brain -- 1.2. Histaminergic receptors in the brain -- 1.3. Histamine in brain diseases -- 1.3.1. Cognitive dysfunction and Alzheimer's disease -- 1.3.2. Motor disorders and Parkinson's disease -- 1.3.3. Schizophrenia -- 1.3.4. Multiple sclerosis -- 1.3.5. Sleep disorders
|
| 505 |
8 |
|
|a 1.3.6. Addictive disorders -- 2. Histaminergic system alterations in Parkinson's disease -- 2.1. Histamine concentration in PD -- 2.2. Histaminergic nerve fibers in PD -- 2.3. Histaminergic gene and receptors in PD -- 2.3.1. HMT and HDC gene expression are altered in PD brain -- 2.3.2. Histamine H3 and H4 receptor expression are altered in PD brain -- 3. Our own investigations on histamine modulation of Parkinson's disease -- 3.1. Methodological consideration -- 3.1.1. Animals -- 3.2. Animal model of PD -- 3.3. Modulation of histaminergic agents
|
| 505 |
8 |
|
|a 3.3.1. Histamine H3 receptor inverse agonist BF2649 -- 3.3.2. Histamine H3 receptor antagonist and partial H4 receptor agonist clobenpropit -- 3.3.3. Anti-histamine mouse monoclonal antibody -- 3.3.4. TiO2 nanodelivery of pharmacological agents -- 3.4. Parameters measured -- 3.4.1. Physiological parameters -- 3.4.2. Physiological variables -- 3.4.3. Blood-brain barrier permeability -- 3.4.3.1. Albumin immunohistochemistry -- 3.4.4. Cerebral blood flow -- 3.4.5. Brain edema formation -- 3.5. Behavioral functions -- 3.5.1. Rota Rod treadmill -- 3.5.2. Immobility during forced swimming
|
| 505 |
8 |
|
|a 4.1.2. Physiological variables in MPTP model of PD -- 4.1.2.1. Mean arterial blood pressure -- 4.1.2.2. Arterial pH -- 4.1.2.3. Arterial PaCO2 -- 4.1.2.4. Arterial PaO2 -- 4.1.2.5. Heart rate -- 4.1.2.6. Respiration rate -- 4.1.3. Behavioral parameters in MPTP model of PD -- 4.1.3.1. Rota-Rod performance -- 4.1.3.2. Forced swimming immobility -- 4.1.4. Biochemical parameters of MPTP model of PD -- 4.1.4.1. Tyrosine hydroxylase enzyme -- 4.1.4.2. Dopamine -- 4.1.4.3. DOPAC -- 4.1.5. Hallmarks of biomarkers in MPTP model of PD -- 4.1.5.1. ASNC -- 4.1.5.2. p-tau
|
| 650 |
|
0 |
|a Brain
|x Diseases.
|
| 650 |
|
0 |
|a Brain
|x Diseases
|x Treatment.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
2 |
|a Brain Diseases
|0 (DNLM)D001927
|
| 650 |
|
6 |
|a Cerveau
|x Maladies.
|0 (CaQQLa)201-0001145
|
| 650 |
|
6 |
|a Cerveau
|0 (CaQQLa)201-0001145
|x Maladies
|0 (CaQQLa)201-0001145
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
7 |
|a Brain
|x Diseases.
|2 fast
|0 (OCoLC)fst00837607
|
| 650 |
|
7 |
|a Brain
|x Diseases
|x Treatment.
|2 fast
|0 (OCoLC)fst00837618
|
| 650 |
|
7 |
|a Nanomedicine.
|2 fast
|0 (OCoLC)fst01744350
|
| 655 |
|
4 |
|a Internet Resources.
|
| 655 |
|
4 |
|a Index not Present.
|
| 700 |
1 |
|
|a Sharma, H. S.
|q (Hari Shanker),
|e editor.
|
| 700 |
1 |
|
|a Sharma, Aruna,
|c MD,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Brain protection strategies and nanomedicine.
|b First edition.
|d Amsterdam, Netherlands ; Cambridge, MA, United States : Elsevier, 2021
|z 0323989276
|z 9780323989275
|w (OCoLC)1260131978
|
| 830 |
|
0 |
|a Progress in brain research ;
|v v. 266.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00796123/266
|z Texto completo
|
